Nephrogenic diabetes insipidus (NDI) is a rare genetic condition that affects children.
Kids with NDI can produce up to 20L of urine a day.
NephroDI's co-founders have identified a novel series of AMPK as a potential therapy for Nephrogenic diabetes insipidus (NDI).
Lack of concentration is our focus.
NephroDI Therapeutics is a pharmaceutical company focusing on concentration disorders of the kidney. NephroDI is initially developing an oral drug to treat Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan disease.
We’re addressing unmet challenges
Patients suffering from NDI produce up to 20 liters (or 5 gallons) of urine per day due to an inability of the kidney to concentrate urine normally in response to the hormone vasopressin. Congenital NDI in children is caused by mutations in a vasopressin receptor gene located on the X chromosome. Congenital NDI has a profound impact on children because they must drink up to 20 liters of water per day to avoid severe dehydration. Children who suffer multiple episodes of severe dehydration often end up with mental retardation. Also, children that try to hold their urine frequently suffer from progressive kidney damage.